Should you buy Axsome Therapeutics stock? (NASDAQ:AXSM). Let's see how it does in our automated value investing analysis system.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Axsome Therapeutics to reach your target.
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| AXSM Price (Axsome Therapeutics stock price per share) |
$202.83 | |
| PE Ratio versus Sector | 100% lower than other Healthcare stocks | |
| PE Ratio versus Industry | 100% lower than other Drug Manufacturers - General stocks | |
| Free Cash Flow Jitter | 24% |
Open-market buys and sells reported by Axsome Therapeutics's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-08-06T00:00:00 | TABUTEAU HERRIOT (Chief Executive Officer) | Sell | 4,660 | $213.95 |
| 2026-08-05T00:00:00 | TABUTEAU HERRIOT (Chief Executive Officer) | Sell | 45,004 | $212.01 |
| 2026-07-01T00:00:00 | TABUTEAU HERRIOT (Chief Executive Officer) | Sell | 49,666 | $240.25 |
| 2026-06-11T00:00:00 | JEFFS ROGER | Sell | 286 | $249.12 |
| 2026-06-10T00:00:00 | Coleman Mark | Sell | 643 | $249.00 |
| 2026-06-10T00:00:00 | Mahony Susan | Sell | 300 | $246.18 |
| 2026-06-10T00:00:00 | JEFFS ROGER | Sell | 286 | $246.18 |
| 2026-06-09T00:00:00 | TABUTEAU HERRIOT (Chief Executive Officer) | Sell | 49,670 | $241.01 |
| 2026-06-09T00:00:00 | Mahony Susan | Sell | 300 | $237.21 |
| 2026-06-09T00:00:00 | Pizzie Nick (Chief Financial Officer) | Sell | 33,000 | $240.09 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 3,205,664 shares shorted. With 44,462,410 shares available for purchase and an average trading volume over the past 10 trading days of 536,840, it would take at least 5.971 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
Based on our analysis, we believe that you should not buy Axsome Therapeutics right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.
Advertisement supports free stock analysis content.
Does Axsome Therapeutics have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
We don't yet have enough financial history for Axsome Therapeutics to produce a full worked example. Check back as more data becomes available, or see the current price and research links below.
Most Popular Articles
A Stock Market How To For Novice Investors
Stock Brokers and Investment Brokers
What are Broker Fees (and how to pay less)?
What is a Good Annual Rate of Return?